<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04281862</url>
  </required_header>
  <id_info>
    <org_study_id>ATLAS2020</org_study_id>
    <nct_id>NCT04281862</nct_id>
  </id_info>
  <brief_title>DEXTENZA Compared to Topical Prednisolone in Patients Undergoing Bilateral LASIK Surgery</brief_title>
  <acronym>AtLAS</acronym>
  <official_title>DEXTENZA Compared to Topical Prednisolone in Patients Undergoing Bilateral LASIK</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vance Thompson Vision</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vance Thompson Vision</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine patient preference and treatment outcomes with an intracanalicular dexamethasone&#xD;
      (0.4mg) insert compared to standard steroid drop regimen in the contralateral eye following&#xD;
      bilateral LASIK surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, open-label, single-center, randomized, investigator-sponsored clinical&#xD;
      study seeks to investigate the outcomes of patients undergoing bilateral LASIK surgery with&#xD;
      the treatment of a dexamethasone intracanalicular insert compared to standard of care topical&#xD;
      prednisolone. All eyes will receive treatment. Additionally, all eyes will receive topical&#xD;
      moxifloxacin QID for 1 week.&#xD;
&#xD;
      Twenty patient eyes undergoing bilateral LASIK surgery will be randomized to receive either&#xD;
      Dextenza (Group A) OR standard of care prednisolone acetate 1% QID for 1 week, BID for 1 week&#xD;
      (Group B). The contralateral eye will receive treatment with either DEXTENZA or topical&#xD;
      prednisolone as a comparator based on randomization of first eye to Group A or Group B.&#xD;
      Post-operative evaluations will be performed on Day 1, Day 7, and Month 1 following surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Preference</measure>
    <time_frame>Through Month 1 (Day 28 +/- 3 days)</time_frame>
    <description>As measured by COMTOL adapted survey.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Comfort</measure>
    <time_frame>Through Month 1 (Day 28 +/- 3 days)</time_frame>
    <description>As measured by SPEED Questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular Surface Health</measure>
    <time_frame>Through Month 1 (Day 28 +/- 3 days)</time_frame>
    <description>As measured by corneal staining.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Outcomes</measure>
    <time_frame>Through Month 1 (Day 28 +/- 3 days)</time_frame>
    <description>As measured by uncorrected Visual Acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Pain</measure>
    <time_frame>Through Month 1 (Day 28 +/- 3 days)</time_frame>
    <description>As measured by Ocular Pain Assessment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety Endpoints</measure>
    <time_frame>Through Month 1 (Day 28 +/- 3 days)</time_frame>
    <description>As measured by intraocular pressure increase of 10 mm Hg or greater from baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Endpoints</measure>
    <time_frame>Through Month 1 (Day 28 +/- 3 days)</time_frame>
    <description>As measured by proportion of eyes rescued with additional topical prednisolone treatment or increased frequency of dosing.</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Endpoints</measure>
    <time_frame>Through Month 1 (Day 28 +/- 3 days)</time_frame>
    <description>As measured by occurrence of adverse events.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Refractive Surgery</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dextenza</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical Prednisolone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextenza 0.4Mg Ophthalmic Insert</intervention_name>
    <description>The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Prednisolone</intervention_name>
    <description>Standard of care topical drop treatment</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any adult patient who is planned to undergo bilateral LASIK surgery.&#xD;
&#xD;
          -  Refractive error between the 2 eyes of 2 Diopters or less&#xD;
&#xD;
          -  Willing and able to comply with clinic visits and study related procedures&#xD;
&#xD;
          -  Willing and able to sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under the age of 18.&#xD;
&#xD;
          -  Patients who choose to have monovision after LASIK&#xD;
&#xD;
          -  Patients with corneal pathology that may interfere with LASIK outcomes&#xD;
&#xD;
          -  Patients who are pregnant (must be ruled out in women of child-bearing age with&#xD;
             pregnancy test).&#xD;
&#xD;
          -  Active infectious ocular or systemic disease.&#xD;
&#xD;
          -  Patients with active infectious ocular or extraocular disease.&#xD;
&#xD;
          -  Patients actively treated with local or systemic immunosuppression including systemic&#xD;
             corticosteroids.&#xD;
&#xD;
          -  Patients with known hypersensitivity to Dexamethasone.&#xD;
&#xD;
          -  Patients with severe disease that warrants critical attention, deemed unsafe for the&#xD;
             study by the investigator.&#xD;
&#xD;
          -  Patients with a history of ocular inflammation or macular edema.&#xD;
&#xD;
          -  Patients with allergy or inability to receive topical antibiotic.&#xD;
&#xD;
          -  Patients on systemic non-steroidal anti-inflammatory drugs (NSAID) greater than 1,200&#xD;
             mg/day&#xD;
&#xD;
          -  Patients with a corticosteroid implant (i.e. Ozurdex).&#xD;
&#xD;
          -  Active or history of chronic or recurrent inflammatory eye disease in either eye&#xD;
&#xD;
          -  Ocular pain in either eye&#xD;
&#xD;
          -  Proliferative diabetic retinopathy in either eye&#xD;
&#xD;
          -  Significant macular pathology detected on macular optical coherence tomography&#xD;
             evaluation at the screening visit in either eye&#xD;
&#xD;
          -  Laser or incisional ocular surgery during the study period and 6 months prior in&#xD;
             either eye&#xD;
&#xD;
          -  History of cauterization of the punctum&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vance Thompson Vision ND</name>
      <address>
        <city>W. Fargo</city>
        <state>North Dakota</state>
        <zip>58078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Thiede</last_name>
      <phone>701-566-5390</phone>
      <email>sarah.thiede@vancethompsonvision.com</email>
    </contact>
    <contact_backup>
      <last_name>Jake Hutchison</last_name>
      <phone>701-566-5390</phone>
      <email>jake.hutchison@vancethompsonvision.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Greenwod, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicholas Risbrudt, OD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2020</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

